68Ga-DOTA-RGD2 Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics

Parihar, Ashwin Singh; Mittal, Bhagwant Rai; Kumar, Rajender; Shukla, Jaya; Bhattacharya, Anish

doi:10.1089/thy.2019.0450

Cited by 29 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a study focused on its detection rate of BM from DTC and a direct comparison with other functional imaging techniques is still lacking [40]. Another 68 Ga-labeled radiotracer ( 68 Ga-DOTA-RGD2), an angiogenic marker, has been studied in RAI-refractory DTC patients showing similar accuracy in detecting BM, albeit in a small sized cohort [41].…”

Section: Diagnostic Rolementioning

confidence: 99%

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Nervo

Ragni

Retta

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

Bone represents the second most common site of distant metastases in differentiated thyroid cancer (DTC). The clinical course of DTC patients with bone metastases (BM) is quite heterogeneous, but generally associated with low survival rates. Skeletal-related events might be a serious complication of BM, resulting in high morbidity and impaired quality of life. To achieve disease control and symptoms relief, multimodal treatment is generally required: radioiodine therapy, local procedures-including surgery, radiotherapy and percutaneous techniques-and systemic therapies, such as kinase inhibitors and antiresorptive drugs. The management of DTC with BM is challenging: a careful evaluation and a personalized approach are essential to improve patients' outcomes. To date, prospective studies focusing on the main clinical aspects of DTC with BM are scarce; available analyses mainly include cohorts assembled over multiple decades, small samples sizes and data about BM not always separated from those regarding other distant metastases. The aim of this review is to summarize the most recent evidences and the unsolved questions regarding BM in DTC, analyzing several key issues: pathophysiology, prognostic factors, role of anatomic and functional imaging, and clinical management.

show abstract

Section: Diagnostic Rolementioning

confidence: 99%

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Nervo

Ragni

Retta

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Few previous studies have also shown that most of the recurrences are noted in the area of the neck and thorax, although most of them have not detailed the sites of distant metastases [ Table 4 ]. [ 18 27 28 29 30 31 32 33 ] In our study, only four patients showed distant metastases to the brain, skull, acetabulum, and sacrum outside the proposed limited PET CT field of view. However, all these lesions were known by previous WBS or clinical history.…”

Section: Discussionmentioning

confidence: 59%

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

et al. 2020

View full text Add to dashboard Cite

Purpose of the Study: 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is used in the management of recurrent differentiated thyroid cancer (DTC) patients presented with rising thyroglobulin (Tg) or anti-Tg antibody (Atg) levels and negative whole-body I-131 scan (WBS). We aimed to evaluate the utility of regional or limited PET/CT in a large population preset with variable Tg/(ATg) levels. Materials and Methods: In a retrospective study, we analyzed 137 PET/CT done on DTC patients presented with raised Tg/Atg and negative WBS. Retrospective evaluation of other available clinical information was done. Results: One hundred and thirty-seven patients aged 8–72 years (41 ± 17.7 years) were included in the study. Eighty-nine (64.9%) patients had positive findings on 18 F-FDG PET-CT. It included thyroid bed recurrence, cervical, mediastinal lymphadenopathy, lung, and bone lesions. In addition, 36 patients had metabolically inactive lung nodules detected on CT. Serum Tg and female sex were the only predictors for a positive PET scan. In most (97.1%) of the patients, the disease was limited to the neck and thoracic region. Conclusions: PET/CT is an excellent imaging modality for evaluating DTC patients presented with biochemical recurrence. It not only finds the disease in more than 80% of the patients but also detects distant metastatic disease, which precludes regional therapies. Lesions were noted mostly in the neck and thoracic region with very few distant skeletal metastases (4/137 patients). In most of the patients, routine vertex to mid-thigh imaging could be avoided.

show abstract

“…Recently, the dimeric [ 68 Ga]Ga-DOTA-RGD 2 has been successfully applied for PET imaging of RR-DTCs in clinical settings [85], showing sensitivity, specificity, and accuracy of 82.3%, 100%, and 86.4%, respectively, which exceeds the same measurements in [ 18 F]FDG of 82.3%, 50%, and 75%, respectively. For RR-DTCs, the advantage provided by [ 68 Ga]Ga-DOTA-RGD2 is the ability to detect lesions not detected by [ 18 F]FDG [85] (Figure 5). Furthermore, diagnosis of RR-DTCs using [ 68 Ga]Ga-DOTA-RGD 2 is better accompanied by [ 177 Lu]Lu-DOTA-RGD 2 , a potential treatment option for RR-DTCs [86].…”

Section: αVβ3 Integrin-targeting Probesmentioning

confidence: 94%

“…RGD and RGD 2 are peptides that bind integrin αvβ3 [84]. Recently, the dimeric [ 68 Ga]Ga-DOTA-RGD 2 has been successfully applied for PET imaging of RR-DTCs in clinical settings [85], showing sensitivity, specificity, and accuracy of 82.3%, 100%, and 86.4%, respectively, which exceeds the same measurements in [ 18 F]FDG of 82.3%, 50%, and 75%, respectively. For RR-DTCs, the advantage provided by [ 68 Ga]Ga-DOTA-RGD2 is the ability to detect lesions not detected by [ 18 F]FDG [85] (Figure 5).…”

Section: αVβ3 Integrin-targeting Probesmentioning

confidence: 96%

Next-Generation Molecular Imaging of Thyroid Cancer

Jin

Liu

Younis

et al. 2021

Cancers

View full text Add to dashboard Cite

An essential aspect of thyroid cancer (TC) management is personalized and precision medicine. Functional imaging of TC with radioiodine and [18F]FDG has been frequently used in disease evaluation for several decades now. Recently, advances in molecular imaging have led to the development of novel tracers based on aptamer, peptide, antibody, nanobody, antibody fragment, and nanoparticle platforms. The emerging targets—including HER2, CD54, SHP2, CD33, and more—are promising targets for clinical translation soon. The significance of these tracers may be realized by outlining the way they support the management of TC. The provided examples focus on where preclinical investigations can be translated. Furthermore, advances in the molecular imaging of TC may inspire the development of novel therapeutic or theranostic tracers. In this review, we summarize TC-targeting probes which include transporter-based and immuno-based imaging moieties. We summarize the most recent evidence in this field and outline how these emerging strategies may potentially optimize clinical practice.

show abstract

⁶⁸Ga-DOTA-RGD₂ Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with ¹⁸F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics

Cited by 29 publications

References 32 publications

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

Next-Generation Molecular Imaging of Thyroid Cancer

Contact Info

Product

Resources

About

68Ga-DOTA-RGD2 Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics

Cited by 29 publications

References 32 publications

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

The utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

Next-Generation Molecular Imaging of Thyroid Cancer

Contact Info

Product

Resources

About

⁶⁸Ga-DOTA-RGD₂ Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with ¹⁸F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan